ChartMill · Mar 9, 2026
Myomo Inc (NYSEARCA:MYO) Reports Mixed Q4 Results Amid Strategic Shift
Myomo beats Q4 revenue estimates but widens loss, prioritizing a strategic shift to recurring revenue channels over short-term profitability.
MY
NYSE · MYO
Myomo, Inc.
Healthcare · Medical - Devices
$1.61
Down-$0.03 (-1.86%)
Updated Oct 7, 2026, 3:13 PM
SID Score
7.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 41.85M
- P/E ratio
- -4.86
- Dividend yield
- 0.00%
- 52-week range
- $0.61 – $1.89
- Volume
- 333.88K
- Avg. volume
- 1.55M
Price performance · MYO
MYO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
MYO closed at $1.61 after 21 trading sessions, up 20.15% for the selected period.
- Last close
- $1.61
- Period change
- +20.15%
- Period low
- $1.24
- Period high
- $1.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $1.73 | $1.78 | $1.59 | $1.61 | 333.88K |
| Oct 5, 2026 | $1.60 | $1.725 | $1.60 | $1.67 | 272.91K |
| Oct 2, 2026 | $1.64 | $1.6999 | $1.61 | $1.63 | 171.79K |
| Oct 1, 2026 | $1.54 | $1.65 | $1.51 | $1.61 | 305.61K |
| Sep 30, 2026 | $1.61 | $1.63 | $1.49 | $1.56 | 368.18K |
| Sep 29, 2026 | $1.58 | $1.61 | $1.54 | $1.57 | 133.74K |
| Sep 28, 2026 | $1.57 | $1.675 | $1.56 | $1.56 | 278.72K |
| Sep 25, 2026 | $1.66 | $1.70 | $1.60 | $1.61 | 221.03K |
| Sep 24, 2026 | $1.63 | $1.67 | $1.585 | $1.67 | 273.18K |
| Sep 23, 2026 | $1.65 | $1.68 | $1.58 | $1.64 | 296.16K |
| Sep 22, 2026 | $1.55 | $1.71 | $1.5303 | $1.64 | 603.66K |
| Sep 21, 2026 | $1.51 | $1.58 | $1.47 | $1.57 | 352.75K |
| Sep 18, 2026 | $1.33 | $1.515 | $1.3117 | $1.48 | 667.79K |
| Sep 17, 2026 | $1.32 | $1.37 | $1.27 | $1.33 | 503.81K |
| Sep 16, 2026 | $1.24 | $1.31 | $1.21 | $1.29 | 776.09K |
| Sep 15, 2026 | $1.31 | $1.31 | $1.23 | $1.24 | 327.39K |
| Sep 14, 2026 | $1.27 | $1.32 | $1.2408 | $1.30 | 292.96K |
| Sep 11, 2026 | $1.30 | $1.325 | $1.25 | $1.30 | 324.94K |
| Sep 10, 2026 | $1.31 | $1.375 | $1.295 | $1.30 | 234.35K |
| Sep 9, 2026 | $1.35 | $1.37 | $1.31 | $1.33 | 190.25K |
| Sep 8, 2026 | $1.41 | $1.46 | $1.33 | $1.34 | 434.67K |
Latest MYO news
The latest Smart Investors Daily articles mentioning MYO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
MYO research
Overview
Company profile and research snapshot.
Company profile
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $8.00
- Implied upside
- —
- Analysts
- 9
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Ascendiant Capital | Buy | — |
| Jun 8, 2026 | Ascendiant Capital | Buy | — |
| Sep 22, 2025 | Ascendiant Capital | Buy | — |
| Aug 12, 2025 | HC Wainwright & Co. | Buy | — |
| Jun 23, 2025 | Craig-Hallum | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Mar 9, 2026
Myomo, Inc. (MYO) Q4 2025 Earnings Call Transcript
Myomo, Inc. (MYO) Q4 2025 Earnings Call March 9, 2026 4:30 PM EDTCompany ParticipantsPaul Gudonis - President, CEO & ChairmanDavid Henry - Chief...
Benzinga · Mar 9, 2026
Myomo Signs Agreement With Elevance Health Over Commercial, Medicare Advantage, Medicaid Plans; Expand Myomo's MyoPro Powered Arm And Hand Orthoses
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has
Benzinga · Mar 9, 2026
Earnings Breakdown: Myomo Q4
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
